High-quality vision possible after multifocal IOL implantation in patient series

Chicago-The ReZoom multifocal IOL (AMO) provides excellent distance vision and useful near and intermediate vision to afford complete spectacle independence for 80% to 90% of implanted patients, said Michael C. Knorz, MD, at the refractive surgery subspecialty day meeting sponsored by the International Society of Refractive Surgery of the American Academy of Ophthalmology.

Dr. Knorz, professor of ophthalmology, University Medical Center Mannheim, Germany, presented results from a series of 12 patients who had the ReZoom IOL implanted in both eyes. He also compared their outcomes with published data for two other multifocal IOLs: the ReStor (Alcon Laboratories) and the Array (AMO).

Consistent with the fact that the ReZoom is a distance-dominant IOL, the proportion of patients able to see 20/20 or better uncorrected visual acuity at distance was slightly higher for the ReZoom IOL compared with the ReStor IOL, whereas a slightly higher proportion of ReStor patients achieved uncorrected near acuity of J1 or better. Rates of patients able to see 20/40 or better at distance and J3 or better at near were similar for the two IOLs.

Dr. Knorz also reported that in his ReZoom series, 90% of patients were spectacle independent for distance, 90% were spectacle independent for intermediate vision tasks, and about 80% did not need correction for near vision.

Analysis of problems with halos at night was investigated using Array data for comparison. Among patients implanted with the ReZoom IOL, complaints of halos at night when they occurred were generally rated as mild, whereas higher proportions of patients implanted with the Array IOL were experiencing moderate and severe halos at night.

“The ReZoom IOL is a multifocal refractive IOL featuring optics technology that distributes light over five optical zones for enhanced restoration of visual function and reduction of photic phenomena,” Dr. Knorz said. “The clinical outcomes achieved in these patients indicate the design seems to work.”